Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
Department of Neurosurgery, Duke University School of Medicine, Durham, NC, USA.
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105. doi: 10.1093/neuonc/noab200.
The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the CDC and NCI, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy and is the first CBTRUS Report to provide the distribution of molecular markers for selected brain and CNS tumor histologies. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.25 (Malignant AAAIR=7.06, Non-malignant AAAIR=17.18). This overall rate was higher in females compared to males (26.95 versus 21.35) and non-Hispanics compared to Hispanics (24.68 versus 22.12). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.3% of all tumors and 49.1% of malignant tumors), and the most common non-malignant tumor was meningioma (39% of all tumors and 54.5% of non-malignant tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.21. An estimated 88,190 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US population in 2021 (25,690 malignant and 62,500 non-malignant). There were 83,029 deaths attributed to malignant brain and other CNS tumors between 2014 and 2018. This represents an average annual mortality rate of 4.43 per 100,000 and an average of 16,606 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 66.9%, for a non-malignant brain and other CNS tumors the five-year relative survival rate was 92.1%.
美国中央脑肿瘤登记处（CBTRUS）与疾病预防控制中心和美国国家癌症研究所合作，是美国最大的专注于原发性脑肿瘤和其他中枢神经系统（CNS）肿瘤的基于人群的登记处，代表了整个美国人口。本报告包含了最新的基于人群的原发性脑肿瘤数据，在完整性和准确性方面超过了以往所有报告，并且是 CBTRUS 首次提供选定脑和 CNS 肿瘤组织学的分子标志物分布的报告。所有比率均使用 2000 年美国标准人口进行年龄调整，并按每 10 万人表示。所有恶性和非恶性脑和其他 CNS 肿瘤的平均年度年龄调整发病率（AAAIR）为 24.25（恶性 AAAIR=7.06，非恶性 AAAIR=17.18）。与男性相比，女性的总体发病率更高（26.95 比 21.35），与西班牙裔相比，非西班牙裔的发病率更高（24.68 比 22.12）。最常见的恶性脑和其他 CNS 肿瘤是胶质母细胞瘤（占所有肿瘤的 14.3%，占恶性肿瘤的 49.1%），最常见的非恶性肿瘤是脑膜瘤（占所有肿瘤的 39%，占非恶性肿瘤的 54.5%）。胶质母细胞瘤在男性中更为常见，脑膜瘤在女性中更为常见。在儿童和青少年（0-19 岁）中，所有原发性脑和其他 CNS 肿瘤的发病率为 6.21。估计 2021 年美国人口中将诊断出 88,190 例新的恶性和非恶性脑和其他 CNS 肿瘤（25,690 例恶性和 62,500 例非恶性）。2014 年至 2018 年间，恶性脑和其他 CNS 肿瘤导致 83,029 人死亡。这代表每 10 万人中有 4.43 人平均每年的死亡率为 4.43，平均每年有 16,606 人死亡。诊断出恶性脑和其他 CNS 肿瘤后，五年相对生存率为 66.9%，而非恶性脑和其他 CNS 肿瘤的五年相对生存率为 92.1%。
